AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06632444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT06054802 — intervention group
Intervention type: DEVICE
Intervention: eCAP
Description: eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
Study NCT06406452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable Tracheobronchial Splint
Description: Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).~The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.~Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires.
Study NCT04918316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corneal gas permeable lens
Description: Fit in corneal gas permeable contact lens first.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine
Description: 1 dose of investigational varicella vaccine administered subcutaneously.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine
Description: 1 dose of marketed varicella vaccine administered subcutaneously.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: 1 dose of hepatitis A vaccine co-administered intramuscularly.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 1 dose of hepatitis A vaccine co-administered intramuscularly.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV (pneumococcal conjugate vaccine) 13
Description: 1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV (pneumococcal conjugate vaccine) 13
Description: 1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 20
Description: 1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: 1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxneuvance
Description: 1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06693895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxneuvance
Description: 1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study NCT06684418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: chest enhanced CT
Description: This is an observational study and patients will receive routine clinical treatment according to the corresponding guidelines. We will collect the enrolled patient's chest enhanced CT and clinicopathological parameters.
Study NCT06701955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and Physical Exam
Description: self administered questionnaires
Study NCT06699875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trak exercise prescription protocol at home
Description: Online exercise protocol using the TRAK software. The patient will undergo 4 weeks of an exercise prescription protocol based on shoulder mobility exercises.
Study NCT06699875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation plan at home
Description: Treatment is based on therapeutic exercise following a conventional rehabilitation plan on paper. The patient will undergo 4 weeks of an exercise prescription protocol based on mobility exercises.
Study NCT06685887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
Study NCT06685887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w
Study NCT06685887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitors
Description: Tislelizumab, 200 mg, q3w
Study NCT06712069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Intraoperative Neurophysiologic Monitoring (MIONM)
Description: Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) is a real-time, device-based intervention used during neurosurgical procedures to monitor and preserve the integrity of neural pathways. It combines the following modalities:~Somatosensory Evoked Potentials (SSEP): Monitors sensory pathways by stimulating peripheral nerves and recording cortical responses.~Motor Evoked Potentials (MEP): Assesses motor pathways via transcranial stimulation and muscle response evaluation.~Electromyography (EMG): Detects nerve irritation and monitors muscle activity during surgery.~This intervention provides critical real-time feedback to the surgical team, enabling immediate adjustments to prevent neurological damage and enhance surgical outcomes. The Cascade IOMAX system is the primary device used in this study for implementing MIONM.
Study NCT06717126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roginolisib
Description: rognolisib
Study NCT06717126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator choice of standard therapy
Description: Investigator will choose the most appropriate treatment standardly given to patients
Study NCT05358548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study NCT05358548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study NCT05358548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study NCT05358548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
Study NCT05358548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: It is a type of immunotherapy and works by helping your immune system to kill cancer cells
Study NCT05347810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of repetitive forces mimicking exoskeleton use
Description: The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
Study NCT06709495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.
Study NCT06709495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.
Study NCT06709495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.
Study NCT06709495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Myeloid growth factor administered per institutional standards.
Study NCT06709495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Myeloid growth factor administered per institutional standards.
Study NCT06731413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Dose of Chemotherapy and Immunotherapy
Description: Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
Study NCT06731868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet 5 mg
Description: LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
Study NCT06731868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet 10 mg
Description: LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
Study NCT06731868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet 20 mg
Description: LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
Study NCT06731868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LPM3770164 sustained release tablet simulant
Description: LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
Study NCT06716151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Study NCT06716151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HB0034 matching placebo
Description: HB0034 matching Palcebo
Study NCT06729385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The blood Proteome Profiling
Description: Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.
Study NCT06255080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training intervention
Description: The intervention consists of making the intervention group practice till proficiency using the 2019-version.~The control group practices till they have reached proficiency using the standard 2016-version.~We wanted to compare time to completetion for the intervention. For the follow-up test we invited all participants to return after 4-6 weeks (where no training was allowed) and made them practice till proficiency again using the standard 2016-version. Time to reach proficiency for the follow-up test was compared.
Study NCT06734975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)
Description: Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.
Study NCT06734975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Superior laryngeal nerve block - Placebo (saline)
Description: Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
Study NCT06733649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: substance abuse treatment education
Description: Perinatal women and the women's community support will receive a 50 minute education session that provides correct information on opioid agonist medications and neonatal abstinence syndrome.
Study NCT06733298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ 14C]-labeled RO7269162
Description: Participants will receive one oral dose of \[14C\]-labeled RO7269162.
Study NCT06731998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia
Description: For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.
Study NCT06731998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Transversus Abdominis Plane block
Description: Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.
Study NCT06737731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1681
Description: SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
Study NCT06739291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIGX1094R
Description: Single drug treatment by SIGX1094R, orally administered once daily.
Study NCT06740331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Study NCT06735378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Cycling
Description: The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
Study NCT06743308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits
Study NCT06743308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits
Study NCT06743308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06743308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06744413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of these three domains will be utilized to maximize their synergistic anabolic effect.~The duration of the program will be set at 4 weeks.
Study NCT06526299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06526299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06526299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT and CT
Study NCT06526299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV
Study NCT06526299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06526299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET-CT Scan
Description: Undergo PSMA PET/CT
Study NCT06526299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06526299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study NCT06742788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is an emerging, non-invasive adjunctive therapy.~The taVNS protocol is set at a pulse width of 500 µs and a frequency of 25 Hz, with an intensity value of 5 mA. The stimulation is to be carried out for a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.~The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.
Study NCT06742788 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous auricular vagus nerve stimulation (staVNS)
Description: The sham transcutaneous auricular vagus nerve stimulation (staVNS) serves as a sub-threshold therapeutic stimulus functions as a sham stimulus. The staVNS protocol is set at a pulse width of 500 µs and a frequency of 1 Hz, with an intensity value of 5 mA. The stimulation is to be carried out for a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime. The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.
Study NCT06469450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: one 40 mg atorvastatin tablet once daily for 28 days
Study NCT06747923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day
Study NCT06747923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day
Study NCT06753838 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sampling of 3 additional BAPA tubes
Description: the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test
Study NCT06760819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: tablet, oral
Study NCT06764628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4375
Description: SHR-4375 injection
Study NCT06766604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Super-GDF9 supplementation during CAPA-IVM
Description: Group 1: donated COCs will be exposed to Super-GDF9 at 50 ng/ml in both the CAPACITATION and MATURATION culture steps.
Study NCT06766604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CAPA-IVM
Description: Group 2: The subject's remaining COCs will be cultured in the CAPA step and the IVM step without the addition of Super-GDF9 during CAPA-IVM.
Study NCT06776471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin-based flowable filling material
Description: Preventive restoration